Abstract
Among pediatric patients, preterm neonates and newborns are the most vulnerable subpopulation. Rapid developmental changes of physiological factors affecting the pharmacokinetics of drug substances in newborns require extreme care in dose and dose regimen decisions. These decisions could be supported by in silico methods such as physiologically-based pharmacokinetic (PBPK) modeling. In a comprehensive literature search, the physiological information of preterm neonates that is required to establish a PBPK model has been summarized and implemented into the database of a generic PBPK software. Physiological parameters include the organ weights and blood flow rates, tissue composition, as well as ontogeny information about metabolic and elimination processes in the liver and kidney. The aim of this work is to evaluate the model’s accuracy in predicting the pharmacokinetics following intravenous administration of two model drugs with distinct physicochemical properties and elimination pathways based on earlier reported in vivo data. To this end, PBPK models of amikacin and paracetamol have been set up to predict their plasma levels in preterm neonates. Predicted plasma concentration-time profiles were compared to experimentally obtained in vivo data. For both drugs, plasma concentrationtime profiles following single and multiple dosing were appropriately predicted for a large range gestational and postnatal ages. In summary, PBPK simulations in preterm neonates appear feasible and might become a useful tool in the future to support dosing decisions in this special patient population.
Keywords: Physiology, preterm, newborn, maturation, pharmacokinetic, amikacin, paracetamol.
Current Pharmaceutical Design
Title:Development of a Physiologically-Based Pharmacokinetic Model for Preterm Neonates: Evaluation with In Vivo Data
Volume: 21 Issue: 39
Author(s): Karina Claassen, Kirstin Thelen, Katrin Coboeken, Thomas Gaub, Jorg Lippert, Karel Allegaert and Stefan Willmann
Affiliation:
Keywords: Physiology, preterm, newborn, maturation, pharmacokinetic, amikacin, paracetamol.
Abstract: Among pediatric patients, preterm neonates and newborns are the most vulnerable subpopulation. Rapid developmental changes of physiological factors affecting the pharmacokinetics of drug substances in newborns require extreme care in dose and dose regimen decisions. These decisions could be supported by in silico methods such as physiologically-based pharmacokinetic (PBPK) modeling. In a comprehensive literature search, the physiological information of preterm neonates that is required to establish a PBPK model has been summarized and implemented into the database of a generic PBPK software. Physiological parameters include the organ weights and blood flow rates, tissue composition, as well as ontogeny information about metabolic and elimination processes in the liver and kidney. The aim of this work is to evaluate the model’s accuracy in predicting the pharmacokinetics following intravenous administration of two model drugs with distinct physicochemical properties and elimination pathways based on earlier reported in vivo data. To this end, PBPK models of amikacin and paracetamol have been set up to predict their plasma levels in preterm neonates. Predicted plasma concentration-time profiles were compared to experimentally obtained in vivo data. For both drugs, plasma concentrationtime profiles following single and multiple dosing were appropriately predicted for a large range gestational and postnatal ages. In summary, PBPK simulations in preterm neonates appear feasible and might become a useful tool in the future to support dosing decisions in this special patient population.
Export Options
About this article
Cite this article as:
Claassen Karina, Thelen Kirstin, Coboeken Katrin, Gaub Thomas, Lippert Jorg, Allegaert Karel and Willmann Stefan, Development of a Physiologically-Based Pharmacokinetic Model for Preterm Neonates: Evaluation with In Vivo Data, Current Pharmaceutical Design 2015; 21 (39) . https://dx.doi.org/10.2174/1381612821666150901110533
DOI https://dx.doi.org/10.2174/1381612821666150901110533 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Therapeutic Approaches in the Stimulation of the Coronary Collateral Circulation
Current Cardiology Reviews Actionable Nutrigenetics for Genetically Based Diseases? A New Critical Path to P4 Medicine
Current Pharmacogenomics and Personalized Medicine Management of Hypertension in Patients with Aortic Valvular Stenosis
Current Hypertension Reviews Extranuclear Localization of SIRT1 and PGC-1α: An Insight into Possible Roles in Diseases Associated with Mitochondrial Dysfunction
Current Molecular Medicine New Patents on Topical Anesthetics
Recent Patents on Inflammation & Allergy Drug Discovery Current and Future Drugs for Appetite Regulation and Obesity Treatment
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) The Pathophysiology of Heart Failure in Children: The Basics
Current Cardiology Reviews Microfluidic System Based on Thermoexpandable Polymer for on Chip Blood Coagulation Testing
Micro and Nanosystems Risk Factors and Potential Preventive Measures for Vascular Disease Progression in Hemodialysis Patients
Vascular Disease Prevention (Discontinued) Treatment of Experimental Myocarditis via Modulation of the Renin-Angiotensin System
Current Pharmaceutical Design Human Heart Failure: A Proteomics Perspective
Current Proteomics The Update of NGAL in Acute Kidney Injury
Current Protein & Peptide Science Quercetin in Attenuation of Ischemic/Reperfusion Injury: A Review
Current Molecular Pharmacology Pulmonary Arterial Hypertension
Current Vascular Pharmacology C. elegans Genetic Networks Predict Roles for O-GlcNAc Cycling in Key Signaling Pathways
Current Signal Transduction Therapy Effects of Physical Exercise on Depressive Symptoms and Biomarkers in Depression
CNS & Neurological Disorders - Drug Targets Accuracy and Reproducibility of Stem Cell Side Population Measurements on Clinically Relevant Products
Current Stem Cell Research & Therapy Pharmacogenomics: Integration into Drug Discovery and Development
Current Topics in Medicinal Chemistry Perspectives in Proteomics: Structural Folds of a Predicted and an Experimentally Determined Cation Channel
Current Proteomics Oxidative-Nitrosative Stress In Hypertension
Current Vascular Pharmacology